Related Experiment Videos
Drug-related thrombosis in hematologic malignancies.
Yona Nadir1, Ron Hoffman, Benjamin Brenner
1Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantaion, Rambam Medical Center, Haifa, Israel. y_segal@ rambam.health.gov.il
Reviews in Clinical and Experimental Hematology
|July 21, 2005
Summary
Cancer drug therapies can increase thrombosis risk through various mechanisms. Further evaluation of heparin and other treatments is crucial for managing these drug-induced thrombotic events in patients.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Cancer patients exhibit a heightened susceptibility to thrombosis.
- Medications used in cancer treatment are significant contributors to hemostatic imbalance and thrombotic events.
- Drug-induced thrombosis involves diverse mechanisms, including enhanced procoagulant activity, reduced anticoagulant synthesis, platelet aggregation, and endothelial damage.
Purpose of the Study:
- To review the role of various drugs in inducing thrombosis in cancer patients.
- To discuss the clinical presentation, pathological mechanisms, and therapeutic strategies for drug-associated thrombotic events.
Main Methods:
- Literature review of drug-induced thrombosis in cancer patients.
- Analysis of specific drug classes and their thrombotic risks, including L-asparaginase, thalidomide, hematopoietic growth factors, and immunosuppressants.
Main Results:
- L-asparaginase is linked to venous thrombotic events; fresh frozen plasma may be insufficient, and heparin requires further study.
- Thalidomide, especially in combination chemotherapy, has emerged as a cause of venous thromboembolism.
- Hematopoietic growth factors (G-CSF, GM-CSF, EPO) and drugs like cyclosporine A, tacrolimus, cisplatin, bleomycin, and gemcitabine are associated with thrombotic events, including thrombotic microangiopathy.
Conclusions:
- Several cancer-related drugs significantly contribute to thrombotic complications.
- Understanding the specific mechanisms and clinical presentations is vital for effective management.
- Further research into optimal therapeutic interventions, such as heparin, is warranted.